Home › Companies › INTELLIA THERAPEUTICS INC. › 2023-2024

INTELLIA THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and INTELLIA THERAPEUTICS INC.’s Form 8-K, filed June 13, 2024 (Item 5.07 on EDGAR). Page generated October 14, 2026.

  • 8Reported items
  • 336Asset managers
  • 1,863Fund votes
  • June 12, 2024Meeting date

Results at a glance

Meeting of June 12, 2024: 2 items on INTELLIA THERAPEUTICS INC.’s Form 8-K, filed June 13, 2024: 2 without a stated outcome.

Material dissent

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore INTELLIA THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by INTELLIA THERAPEUTICS INC.

These tallies are INTELLIA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 13, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

INTELLIA THERAPEUTICS INC. — official shareholder meeting results, meeting held June 12, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Fred Cohen, M.D., D.Phil. 65,390,554---- 6,655,84611,843,099 91%Not verified—
Elect Director: Frank Verwiel, M.D. 55,820,159---- 16,226,24111,843,099 77%Not verified—

Source: INTELLIA THERAPEUTICS INC., Form 8-K, filed with the SEC on June 13, 2024 — read the filing on EDGAR.

How asset managers voted at the INTELLIA THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 336 asset managers that disclosed a INTELLIA THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of INTELLIA THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Elect Director: Frank Verwiel, M.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

77% Majority: yes · of votes cast

FOR 77%WITHHELD
FOR: 55,820,159WITHHELD: 16,226,241
Details: description as filed, official tally, votes by 85 asset managers

Description as filed by funds: Election of Directors. Election of the following individuals nominated to serve as Class II directors, for a three-year term ending at the annual meeting of stockholders to be held in 2027: Frank Verwiel, M.D.

INTELLIA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Frank Verwiel, M.D.”): 55,820,159 for, 16,226,241 withheld, per its Form 8-K filed June 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 77% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 85 asset managers below reported 34,602,219 for, 70 against, 2,789,197 withheld, 140,555 abstained.

FOR
FOR: 34,602,219AGAINST: 70ABSTAIN: 140,555WITHHOLD: 2,789,197
Largest asset managers voting on “Election of Directors. Election of the following individuals nominated to serve as Class II directors, for a t” at INTELLIA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard12,223,9330 00For
ARK ETF Trust9,826,7340 00For
Fidelity2,559,2990 019,978For
State Street2,434,8280 035,401For
Federated Hermes1,929,7000 00For
BlackRock1,404,1460 00For
T. Rowe Price1,179,1780 00For
Charles Schwab730,0220 00For
AllianceBernstein00 0546,754Withhold
Dimensional00 0510,760Withhold
Equitable175,3030 0205,641Mixed
TIAA369,0330 00For
AB DISCOVERY GROWTH FUND, INC.00 0304,792Withhold
Morgan Stanley269,6350 00For
AMERICAN BEACON FUNDS252,2700 00For
Global X174,6650 00For
QUANTITATIVE MASTER SERIES LLC167,0970 00For
Direxion Shares ETF Trust00 0162,429Withhold
Goldman Sachs00 0160,000Withhold
Hartford159,7640 00For
Aberdeen00 0154,269Withhold
Principal5790 0119,620Withhold
JPMorgan109,0270 00For
Jackson National00 94,5610Abstain
Lincoln Financial79,5360 08,782Mixed

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

2. Elect Director: Fred Cohen, M.D., D.Phil.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 6 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%
FOR: 65,390,554WITHHELD: 6,655,846
Details: description as filed, official tally, votes by 85 asset managers

Description as filed by funds: Election of Directors. Election of the following individuals nominated to serve as Class II directors, for a three-year term ending at the annual meeting of stockholders to be held in 2027: Fred Cohen, M.D., D.Phil.

INTELLIA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Fred Cohen, M.D., D.Phil.”): 65,390,554 for, 6,655,846 withheld, per its Form 8-K filed June 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 91% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 85 asset managers below reported 33,600,653 for, 3,789,853 withheld, 141,535 abstained.

FOR
FOR: 33,600,653ABSTAIN: 141,535WITHHOLD: 3,789,853
Largest asset managers voting on “Election of Directors. Election of the following individuals nominated to serve as Class II directors, for a t” at INTELLIA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard12,223,9330 00For
ARK ETF Trust9,826,7340 00For
Fidelity2,559,2990 019,978For
State Street2,463,3280 06,901For
Federated Hermes00 01,929,700Withhold
BlackRock1,404,1460 00For
T. Rowe Price1,179,1780 00For
Charles Schwab730,0220 00For
AllianceBernstein00 0546,754Withhold
Dimensional00 0510,760Withhold
Equitable175,3030 0205,641Mixed
TIAA369,0330 00For
AB DISCOVERY GROWTH FUND, INC.00 0304,792Withhold
Morgan Stanley269,6350 00For
AMERICAN BEACON FUNDS252,2700 00For
Global X174,6650 00For
QUANTITATIVE MASTER SERIES LLC167,0970 00For
Direxion Shares ETF Trust162,4290 00For
Goldman Sachs160,0000 00For
Hartford159,7640 00For
Aberdeen154,2690 00For
Principal10,5640 0109,635Mixed
JPMorgan00 109,0270Abstain
Jackson National78,7550 15,8060Mixed
Lincoln Financial77,2430 6,2364,839Mixed

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

3. Approval of a second amendment to our Second Amended and Restated Certificate of Incorporation, as amended, to limit…

No official matchCORPORATE GOVERNANCE

Combines 3 wordings of this item as funds reported it.

99% of fund votes cast · no official result

FOR
Details: description as filed, votes by 85 asset managers

Description as filed by funds: Approval of a second amendment to our Second Amended and Restated Certificate of Incorporation, as amended, to limit the liability of certain officers of the Company as permitted by recent amendments to the Delaware General Corporation Law.

The 85 asset managers below reported 37,098,648 for, 414,298 against, 19,095 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 37,098,648AGAINST: 414,298ABSTAIN: 19,095
Largest asset managers voting on “Approval of a second amendment to our Second Amended and Restated Certificate of Incorporation, as amended, to” at INTELLIA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard12,223,9330 00For
ARK ETF Trust9,826,7340 00For
Fidelity2,579,2770 00For
State Street2,466,0564,173 00For
Federated Hermes1,929,7000 00For
BlackRock1,404,1460 00For
T. Rowe Price1,179,1780 00For
Charles Schwab730,0220 00For
AllianceBernstein546,7540 00For
Dimensional510,7600 00For
Equitable380,9440 00For
TIAA369,0330 00For
AB DISCOVERY GROWTH FUND, INC.304,7920 00For
Morgan Stanley269,6350 00For
AMERICAN BEACON FUNDS252,2700 00For
Global X0174,665 00Against
QUANTITATIVE MASTER SERIES LLC167,0970 00For
Direxion Shares ETF Trust162,4290 00For
Goldman Sachs160,0000 00For
Hartford159,7640 00For
Aberdeen154,2690 00For
Principal120,1990 00For
JPMorgan0109,027 00Against
Jackson National94,5610 00For
Lincoln Financial82,0826,236 00Mixed

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

4. Approve, on a non-binding advisory basis, the compensation of the named executive officers.

Combines 9 wordings of this item as funds reported it.

99% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: votes by 323 asset managers

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 84 asset managers voting on “Approve, on a non-binding advisory basis, the compensation of the named executive officers.” at INTELLIA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard12,223,9330 00For
ARK ETF Trust9,826,7340 00For
Fidelity2,579,2770 00For
State Street2,470,2290 00For
Federated Hermes1,929,7000 00For
BlackRock1,404,1460 00For
T. Rowe Price1,179,1780 00For
Charles Schwab730,0220 00For
AllianceBernstein546,7540 00For
Dimensional510,7600 00For
Equitable380,9440 00For
TIAA369,0330 00For
AB DISCOVERY GROWTH FUND, INC.304,7920 00For
Morgan Stanley269,6350 00For
AMERICAN BEACON FUNDS252,2700 00For
Global X174,6650 00For
QUANTITATIVE MASTER SERIES LLC167,0970 00For
Direxion Shares ETF Trust162,4290 00For
Goldman Sachs160,0000 00For
Hartford159,7640 00For
Aberdeen154,2690 00For
Principal120,1990 00For
JPMorgan109,0270 00For
Jackson National94,5610 00For
Lincoln Financial88,3180 00For

Fund voting reports, all 84 managers: 37,500,134 for, 12,742 against, 19,095 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 265 asset managers voting on “Approve, on a non-binding advisory basis, the compensation of the named executive officers.” at INTELLIA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Deep Track Capital, LP4,236,9860 00For
State Street4,123,2980 00For
Wellington3,940,0320 00For
Nikko Asset Management Americas, Inc.3,026,6000 00For
BlackRock2,043,4380 00For
Federated Hermes1,929,7000 00For
T. Rowe Price1,549,7550 00For
Fidelity1,517,4409,629 00For
Contrarius Investment Management Ltd1,450,0330 00For
AllianceBernstein1,393,0430 00For
GEODE CAPITAL MANAGEMENT, LLC1,137,0750 00For
CHEVY CHASE TRUST Co1,033,8430 00For
Charles Schwab744,9350 00For
PICTET ASSET MANAGEMENT SA693,5630 00For
Northern Trust506,77359 00For
Two Sigma501,5670 00For
Morgan Stanley439,0900 00For
MPM BioImpact LLC433,9410 00For
Nuveen383,8470 00For
Nikko Asset Management Co., Ltd.347,2390 00For
Vestmark Advisory Solutions, Inc.346,0260 00For
NOMURA ASSET MANAGEMENT CO LTD0306,366 00Against
CAPITAL ADVISORS INC/OK270,6490 00For
Goldman Sachs216,9460 00For
Opaleye Management Inc.205,0000 00For

Institutional-manager reports, all 265 managers: 35,897,584 for, 1,014,564 against, 10,203 not voted. Showing the 25 largest; see all in the interactive database.

5. 14A Executive Compensation

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

99.7% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: votes by 7 asset managers

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 1 asset manager voting on “14A Executive Compensation” at INTELLIA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Ultimus Managers Trust10,9150 00For

Fund voting reports, all 1 managers: 10,915 for.

Institutional-manager reports: 6 asset managers voting on “14A Executive Compensation” at INTELLIA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Orchard Capital Management, LLC160,6050 00For
NICHOLS & PRATT ADVISERS LLP /MA0400 00Against
TOWNSEND ASSET MANAGEMENT CORP /NC/ /ADV3120 00For
PEDDOCK CAPITAL ADVISORS, LLC2020 00For
Investment Partners Asset Management, Inc.00 450Abstain
GRIMES & COMPANY, INC.280 00For

Institutional-manager reports, all 6 managers: 161,147 for, 400 against, 45 abstained.

6. Advisory Vote to Ratify Named Executive Officers' Compensation

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTESSECTION 14A SAY-ON-PAY VOTESSECTION 14A SAY-ON-PAY VOTESSECTION 14A SAY-ON-PAY VOTES

99.2% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: votes by 7 asset managers

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 1 asset manager voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at INTELLIA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Advisors' Inner Circle Fund III23,0520 00For

Fund voting reports, all 1 managers: 23,052 for.

Institutional-manager reports: 6 asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at INTELLIA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Rokos Capital Management LLP1,463,6300 00For
JPMorgan409,6230 00For
Desjardins Global Asset Management Inc.014,419 00Against
TD ASSET MANAGEMENT INC2500 00For
SCHARF INVESTMENTS, LLC2280 00For
Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma700 00For

Institutional-manager reports, all 6 managers: 1,873,801 for, 14,419 against.

7. Ratification of the appointment of Deloitte & Touche LLP as Intellia's independent registered public accounting firm…

No official matchAUDIT-RELATED

Combines 4 wordings of this item as funds reported it.

99.9% of fund votes cast · no official result

FOR
Details: description as filed, votes by 85 asset managers

Description as filed by funds: Ratification of the appointment of Deloitte & Touche LLP as Intellia's independent registered public accounting firm for the fiscal year ending December 31, 2024

The 85 asset managers below reported 37,508,773 for, 4,173 against, 19,095 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 37,508,773AGAINST: 4,173ABSTAIN: 19,095
Largest asset managers voting on “Ratification of the appointment of Deloitte & Touche LLP as Intellia's independent registered public accountin” at INTELLIA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard12,223,9330 00For
ARK ETF Trust9,826,7340 00For
Fidelity2,579,2770 00For
State Street2,466,0564,173 00For
Federated Hermes1,929,7000 00For
BlackRock1,404,1460 00For
T. Rowe Price1,179,1780 00For
Charles Schwab730,0220 00For
AllianceBernstein546,7540 00For
Dimensional510,7600 00For
Equitable380,9440 00For
TIAA369,0330 00For
AB DISCOVERY GROWTH FUND, INC.304,7920 00For
Morgan Stanley269,6350 00For
AMERICAN BEACON FUNDS252,2700 00For
Global X174,6650 00For
QUANTITATIVE MASTER SERIES LLC167,0970 00For
Direxion Shares ETF Trust162,4290 00For
Goldman Sachs160,0000 00For
Hartford159,7640 00For
Aberdeen154,2690 00For
Principal120,1990 00For
JPMorgan109,0270 00For
Jackson National94,5610 00For
Lincoln Financial88,3180 00For

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

8. Ratify Appointment of IndependentAuditors

No official matchAUDIT-RELATED

100% of fund votes cast · no official result

FOR
Details: votes by 2 asset managers

The 2 asset managers below reported 33,967 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 33,967
Largest asset managers voting on “Ratify Appointment of IndependentAuditors” at INTELLIA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Advisors' Inner Circle Fund III23,0520 00For
Ultimus Managers Trust10,9150 00For

Largest INTELLIA THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 96,333,373 shares outstanding at the time of that meeting.

Fund voting reports: top INTELLIA THERAPEUTICS INC. shareholders by shares voted on “Approve, on a non-binding advisory basis, the compensation of the named executive officers.”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 12.69%
2ARK ETF Trust 10.20%
3Fidelity 2.68%
4State Street 2.56%
5Federated Hermes 2.00%
6BlackRock 1.46%
7T. Rowe Price 1.22%
8Charles Schwab 0.76%
9AllianceBernstein 0.57%
10Dimensional 0.53%
Institutional-manager reports: top INTELLIA THERAPEUTICS INC. shareholders by shares voted on “Approve, on a non-binding advisory basis, the compensation of the named executive officers.”, 2023-2024
#Asset manager % of shares outstanding
1Deep Track Capital, LP 4.40%
2State Street 4.28%
3Wellington 4.09%
4Nikko Asset Management Americas, Inc. 3.14%
5BlackRock 2.12%
6Federated Hermes 2.00%
7T. Rowe Price 1.61%
8Fidelity 1.59%
9Contrarius Investment Management Ltd 1.51%
10AllianceBernstein 1.45%

Reported INTELLIA THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

INTELLIA THERAPEUTICS INC. holdings and ownership disclosed for the 2023-2024 proxy season
Holder % outstanding Disclosure
Vanguard Group 11.47% 13F
BlackRock 9.63% 13F
Morgan Stanley 6.25% 13F
State Street 4.77% 13F
Goldman Sachs 4.44% 13F
Wellington Management 4.32% 13F
Geode Capital 2.12% 13F
FMR (Fidelity) 1.92% 13F
T. Rowe Price 1.69% 13F
Dimensional Fund Advisors 1.27% 13F

Percentages above are of 96,333,373 shares outstanding, as reported by INTELLIA THERAPEUTICS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from INTELLIA THERAPEUTICS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.

At INTELLIA THERAPEUTICS INC.'s shareholder meeting held June 12, 2024, in the 2023-2024 proxy season, 336 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,863 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. INTELLIA THERAPEUTICS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — Approve, on a non-binding advisory basis, the compensation of the named executive officers. — the reporting funds and managers cast 99% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.

INTELLIA THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.